41 - 45 of 45 results

Publications

Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.

Infographic

ESMO-2025-Peters-Infographic
DAREON®-8: A Phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
SCLC DLL3/CD3 TcE Infographic
ESMO-2025-Wermke-Infographic
DAREON®-9, a Phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients with advanced small cell lung cancer: updated results
Author(s): Wermke et al.
SCLC DLL3/CD3 TcE Infographic
An open-label, Phase Ib dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, PD-L1-positive HNSCC
An open-label, Phase Ib dose-expansion study to assess the efficacy of CD137 FAP agonist BI 765179 plus pembrolizumab as a first-line treatment in metastatic or incurable, PD-L1-positive HNSCC
Author(s): Shroff et al.
HNSCC CD137xFAP bsAb Infographic
Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: Initial results from a Phase Ia study
Author(s): Harrington et al.
Solid tumors STING agonist, PD-1 inhibitor Infographic
A Phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors
A Phase Ia/Ib, dose-escalation/expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors
Author(s): Doi et al.
Solid tumors B7-H6/CD3 TcE, PD-1 inhibitor Infographic

Vault id: SC-CRP-16532